CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 207 enrolled
Drug / intervention
24-Valent Pneumococcal Conjugate Vaccine +1 morebiological
Likely dose
VAX-24: 0.5 ml intramuscular injection at Day 1; Prevnar 20: 0.5 ml intramuscular injection at Day 1AI-extracted
Key inclusion· 4
  • ✓Age 65 years or older
  • ✓In good general health with stable preexisting medical conditions (no treatment changes ≥6 weeks prior)
  • ✓Available for follow-up through 6 months after vaccination
  • ✓Willing to provide blood samples for research
Key exclusion· 12
  • ✕Previous pneumococcal disease (confirmed or self-reported)
  • ✕Previous receipt of any licensed or investigational pneumococcal vaccine
  • ✕Any investigational product within 30 days prior to enrollment or concurrent participation in another interventional study
  • ✕Any licensed vaccine 30 days before enrollment through Day 29

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05297578
NCT05297578Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Observer-Blind, Dose-Finding, Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults 65 Years and Older

Vaxcyte, Inc.·interventional·Posted Mar 28, 2022·Updated Oct 9, 2024

In Brief

A Phase 2 clinical trial evaluating 24-Valent Pneumococcal Conjugate Vaccine and Pneumococcal 20-valent Conjugate Vaccine for Pneumococcal Vaccines. Completed, enrolled 207 participants across 20 sites.

Detailed Summary

The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 65 years of age and older.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Vaccines
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedMar 28, 2022
Enrollment StartJun 15, 2022
Primary CompletionFeb 15, 2023
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.3 years ago

Interventions

24-Valent Pneumococcal Conjugate Vaccinebiological

0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1

Pneumococcal 20-valent Conjugate Vaccinebiological

0.5 ml dose of Prevnar 20 will be administered into the deltoid muscle at Day 1